Cognition Therapeutics Reports Financial Results and Insights on Alzheimer’s Treatment
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases, has recently shared its financial outcomes for the third quarter and provided valuable updates regarding its clinical advancements. Among the notable achievements, results from the Phase 2 SHINE study revealed powerful insights into the efficacy of CT1812, a drug under investigation for treating Alzheimer’s Disease.
Promising Study Results for CT1812 in Alzheimer’s Disease
The Phase 2 SHINE study demonstrated that CT1812 significantly slowed cognitive decline in patients with Alzheimer's disease, particularly in those with lower levels of plasma p-tau217. Remarkably, findings reported a stunning 95% reduction in cognitive decline measured by the ADAS-Cog11 scale and a 108% decrease on the MMSE scale among patients who had p-tau217 levels below the median. This provides compelling evidence that CT1812 could be a groundbreaking approach in addressing Alzheimer’s pathology.
CEO’s Insight on Clinical Developments
Lisa Ricciardi, president and CEO of Cognition Therapeutics, expressed her enthusiasm regarding these results, stating that they mark a significant milestone for the company. "We are making swift progress with CT1812 in Alzheimer's disease, and we plan to engage with the FDA for an end-of-Phase 2 meeting to discuss the drug's profile and the next steps toward a pivotal Phase 3 program," she explained. This engagement with regulatory bodies could shape future research directions.
Upcoming Results from the SHIMMER Study
Alongside the success of the SHINE study, Cognition Therapeutics is preparing to unveil the topline results from its Phase 2 SHIMMER study. This study focuses on patients experiencing mild-to-moderate dementia with Lewy bodies (DLB), a condition gaining attention due to a lack of effective treatment options. The company anticipates sharing results that will provide insights into the safety and efficacy of CT1812 in this under-researched demographic.
Addressing Unmet Needs in Dementia with Lewy Bodies
Dementia with Lewy bodies represents a challenging area within neurodegenerative diseases. Cognition Therapeutics aims to fill this gap by investigating patient responses to CT1812, potentially laying the groundwork for future research that could lead to disease-modifying treatments, which are currently nonexistent for DLB.
Financial Overview for Q3 2024
As of September 30, 2024, Cognition Therapeutics reported approximately $22.0 million in cash and cash equivalents. Furthermore, the total grant funds from the National Institute on Aging (NIA) stood at $53.6 million, indicating a solid financial grounding. This funding is expected to support the company’s operations through mid-2025.
Examination of Operating Expenses
During the third quarter, the company incurred research and development expenses of $11.4 million, slightly down from $11.7 million during the same period a year prior. This reduction reflects decreased costs associated with contract manufacturing organizations, essential for the production required for preclinical and clinical trials. Administrative expenses remained stable, reflecting prudent financial management in maintaining operational efficiency.
Contacting Cognition Therapeutics
For further inquiries, Cognition Therapeutics provides several channels for communication:
- General Inquiries: info@cogrx.com
- Media Contact: Casey McDonald, cmcdonald@tiberend.com
- Investor Relations: Mike Moyer, mmoyer@lifesciadvisors.com
Cognition Therapeutics remains focused on advancing its innovative therapies and providing hope to patients facing challenging neurodegenerative conditions. The company’s commitment to unearthing new pathways for treatment holds promise amidst the growing need for effective solutions against diseases like Alzheimer’s and DLB.
Frequently Asked Questions
What is Cognition Therapeutics known for?
Cognition Therapeutics is focused on developing treatments for neurodegenerative disorders, particularly Alzheimer’s disease and dementia with Lewy bodies.
What outcomes were reported from the recent SHINE study?
The SHINE study revealed that CT1812 significantly slowed cognitive decline in Alzheimer's patients, especially those with lower levels of plasma p-tau217.
When will the SHIMMER study results be available?
The topline results from the SHIMMER study are expected to be reported by the end of this year.
How is Cognition Therapeutics financially positioned?
As of September 30, 2024, the company reported approximately $22 million in cash, along with significant grant funding to support its operations into mid-2025.
How can I contact Cognition Therapeutics for more information?
Inquiries can be directed to info@cogrx.com for general questions, or specific individuals in media and investor relations can be reached via provided email addresses.
